Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PTIX logo PTIX
Upturn stock ratingUpturn stock rating
PTIX logo

Protagenic Therapeutics (PTIX)

Upturn stock ratingUpturn stock rating
$3.32
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/13/2025: PTIX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4Target price
Low$2.35
Current$3.32
high$15.54

Analysis of Past Performance

Type Stock
Historic Profit -55.02%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.21M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 1
Beta 0.38
52 Weeks Range 2.35 - 15.54
Updated Date 06/30/2025
52 Weeks Range 2.35 - 15.54
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -13.13

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -189.6%
Return on Equity (TTM) -512.79%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -1639690
Price to Sales(TTM) -
Enterprise Value -1639690
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.64
Shares Outstanding 868414
Shares Floating 491613
Shares Outstanding 868414
Shares Floating 491613
Percent Insiders 11.21
Percent Institutions 4.75

Analyst Ratings

Rating 1
Target Price 4
Buy 1
Strong Buy -
Buy 1
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Protagenic Therapeutics

stock logo

Company Overview

overview logo History and Background

As of October 26, 2023, Protagenic Therapeutics appears to be a fictitious company or a company with very limited public information available. Therefore, a detailed history, founding year, and milestones cannot be provided. This analysis will be based on a hypothetical company profile.

business area logo Core Business Areas

  • Drug Discovery: Focuses on identifying and developing novel therapeutic peptides for neurological disorders.
  • Preclinical Development: Conducts in vitro and in vivo studies to assess the safety and efficacy of drug candidates.
  • Licensing and Partnerships: Seeks strategic collaborations with pharmaceutical companies to advance clinical development and commercialization.

leadership logo Leadership and Structure

Hypothetically, the company has a CEO with a background in pharmaceutical development and a scientific advisory board composed of leading neurologists and peptide chemists. It has a functional organizational structure with departments for research, preclinical development, and business development.

Top Products and Market Share

overview logo Key Offerings

  • PT-101 (Hypothetical): A novel therapeutic peptide in preclinical development for the treatment of Alzheimer's disease. No market share data exists. Potential competitors include Biogen (BIIB), Eli Lilly (LLY), and Roche (ROG.SW) based on their Alzheimer's drug development programs.
  • PT-202 (Hypothetical): A pre-clinical candidate for anxiety disorders. No market share data is available. Competitors include pharmaceutical companies marketing SSRIs and other anxiety medications, such as Pfizer (PFE) and Johnson & Johnson (JNJ).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, particularly in neurological disorders, is characterized by high unmet needs, lengthy development timelines, and significant regulatory hurdles. The Alzheimer's disease market is a large and growing market due to the aging population.

Positioning

Hypothetically, Protagenic Therapeutics is positioned as an innovative biotechnology company focused on developing peptide-based therapeutics for neurological diseases, targeting specific disease mechanisms. Its competitive advantage would be its novel peptide technology.

Total Addressable Market (TAM)

The Alzheimer's disease market is estimated at tens of billions of dollars annually. Protagenic Therapeutics, being in pre-clinical development, is targeting a portion of this TAM through licensing agreements or direct commercialization if PT-101 reaches the market.

Upturn SWOT Analysis

Strengths

  • Novel peptide technology
  • Experienced leadership team (hypothetical)
  • Strong scientific advisory board (hypothetical)
  • Focus on unmet medical needs

Weaknesses

  • Preclinical stage of development
  • Limited financial resources
  • High risk of drug development failure
  • Dependence on partnerships for clinical development

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Positive clinical trial results
  • Expansion into new therapeutic areas
  • Government funding for research and development

Threats

  • Failure of drug candidates in clinical trials
  • Competition from established pharmaceutical companies
  • Changes in regulatory landscape
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • BIIB
  • LLY
  • PFE
  • JNJ
  • ROG.SW

Competitive Landscape

Protagenic Therapeutics faces significant competition from established pharmaceutical companies with greater resources and established pipelines. Its success depends on the differentiation and efficacy of its peptide therapeutics.

Growth Trajectory and Initiatives

Historical Growth: Not Applicable

Future Projections: Future growth is highly dependent on the success of preclinical and clinical development programs and securing partnerships.

Recent Initiatives: Hypothetically, recent initiatives could include securing seed funding, initiating preclinical studies, and engaging with potential pharmaceutical partners.

Summary

Protagenic Therapeutics, being hypothetical, would be considered a high-risk, high-reward early-stage biotechnology company. Its peptide technology presents potential but needs to clear significant hurdles to reach the market. Securing partnerships and achieving positive preclinical and clinical results are critical for its survival and growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Hypothetical data and publicly available information on similar biotechnology companies.

Disclaimers:

This analysis is based on a hypothetical company and should not be considered investment advice. Actual financial performance and market conditions may differ significantly.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Protagenic Therapeutics

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2016-01-05
President, CEO & Director Mr. Barrett Evans
Sector Healthcare
Industry Biotechnology
Full time employees 1
Full time employees 1

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.